In a filing, Cytokinetics Inc revealed its EVP Research & Development Malik Fady Ibraham unloaded Company’s shares for reported $76620.0 on Aug 19 ’25. In the deal valued at $38.31 per share,2,000 shares were sold. As a result of this transaction, Malik Fady Ibraham now holds 140,610 shares worth roughly $5.2 million.
Then, Blum Robert I sold 5,000 shares, generating $192,100 in total proceeds. Upon selling the shares at $38.42, the President & CEO now owns 383,108 shares.
Before that, Malik Fady Ibraham sold 2,000 shares. Cytokinetics Inc shares valued at $72,680 were divested by the EVP Research & Development at a price of $36.34 per share. As a result of the transaction, Malik Fady Ibraham now holds 140,610 shares, worth roughly $5.2 million.
A number of analysts have revised their coverage, including Barclays’s analysts, who began to cover the stock in late April with a ‘”an Overweight”‘ rating. Citigroup began covering CYTK with “Buy” recommendation on February 07, 2025. Stifel started covering the stock on January 22, 2025. It rated CYTK as “a Buy”.
Price Performance Review of CYTK
On Monday, Cytokinetics Inc [NASDAQ:CYTK] saw its stock fall -3.47% to $37.01. Over the last five days, the stock has lost -4.98%. Cytokinetics Inc shares have fallen nearly -34.59% since the year began. Nevertheless, the stocks have fallen -21.32% over the past one year. While a 52-week high of $59.39 was reached on 01/27/25, a 52-week low of $29.31 was recorded on 05/15/25.
Levels Of Support And Resistance For CYTK Stock
The 24-hour chart illustrates a support level at 36.30, which if violated will result in even more drops to 35.59. On the upside, there is a resistance level at 38.42. A further resistance level may holdings at 39.84.
How much short interest is there in Cytokinetics Inc?
A steep rise in short interest was recorded in Cytokinetics Inc stocks on 2025-07-31, growing by 0.5 million shares to a total of 15.52 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-30 was 15.02 million shares. There was a rise of 3.22%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on November 08, 2024 when RBC Capital Mkts began covering the stock and recommended ‘”an Outperform”‘ rating along with a $80 price target.
